IPHA is Innate Pharma S.A. (Healthcare) — a non-dividend-paying stock. Trading at $2.08. Market cap: $232M.
Stock snapshot
| Price | $2.08 |
| Market cap | $232M |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
About IPHA
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Frequently asked
What is IPHA's current stock price?
IPHA (Innate Pharma S.A.) is currently trading at $2.08.
Does IPHA pay a dividend?
IPHA (Innate Pharma S.A.) does not currently pay a regular dividend.
Track IPHA in DiviDrip
Add IPHA to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search IPHA and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-05. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.